← Leaderboards
Evi X. Stavrou
Louis Stokes Cleveland Va Medical Center
$2,965,635
Attributed
$3,676,486
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,676,486 · 3
VA$0 · 1
By mechanism
R01$3,373,050 · 2
TL1$303,436 · 1
I01$0 · 1
Top collaborators
- Rafal L Pawlinski2 shared
Most similar at Louis Stokes Cleveland Va Medical Center
Same institution · by research overlap
- Ronald J Triolo$12,565,467
Others in their field
Other Emerging Leaders on “Basic Science”
- Leonard Freedman · Leidos Biomedical Research, Inc.$106,162,603
- Julie Ake · National Institute Of Allergy And Infectious Diseases$52,642,120
- Sujatha Rashid · American Type Culture Collection$48,624,582
- Scott Hensley · University Of Pennsylvania$47,224,291
- John Hobbs · Suny At Stony Brook$41,239,084
- Christopher Bee · Suny At Stony Brook$41,239,084
Research focus
Basic ScienceNeutrophilAdhesionsNovel StrategiesUrokinase Plasminogen Activator ReceptorSurfaceIn VivoMouse ModelFutureNeutrophil ActivationReceptor BindingPeptidesSignal TransductionSitePathologyFoundationsMediatingMorbidity - Disease RateEventBindingFactor XiiInnovationDesignAutocrine
Grant awards (12)
Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease$696,975
R01 · FY2025 · HL
KUH-TN Training Core$303,436
TL1 · FY2025 · DK · contact PI
Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease$724,727
R01 · FY2024 · HL
Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic Wounds$390,297
R01 · FY2023 · HL · contact PI
Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils$0
I01 · FY2023 · VA · contact PI
Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic Wounds$390,766
R01 · FY2022 · HL · contact PI
Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils$0
I01 · FY2022 · VA · contact PI
Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic Wounds$391,217
R01 · FY2021 · HL · contact PI
Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils$0
I01 · FY2021 · VA · contact PI
Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic Wounds$389,329
R01 · FY2020 · HL · contact PI
Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils$0
I01 · FY2020 · VA · contact PI
Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic Wounds$389,739
R01 · FY2019 · HL · contact PI